Literature DB >> 21550042

Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.

Bruce S Shapiro1, Said T Daneshmand, Forest C Garner, Martha Aguirre, Cynthia Hudson.   

Abstract

This retrospective study of fresh autologous blastocyst transfers in high responders compared ongoing pregnancy rates in cycles that followed trigger with GnRH agonist (GnRHa) alone with standard luteal support, GnRHa alone with enhanced luteal support, or GnRHa with concomitant low-dose hCG (dual trigger). Ongoing pregnancy rates were significantly increased with the dual trigger or with enhanced luteal support, whereas the incidence of clinically significant ovarian hyperstimulation syndrome was 0.0% in the groups receiving only GnRHa and 0.5% (1 of 182) in patients receiving GnRHa with concomitant low-dose hCG.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550042     DOI: 10.1016/j.fertnstert.2011.03.109

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  37 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

Review 2.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

3.  Combined GnRH-agonist and human chorionic gonadotropin trigger improves ICSI cycle outcomes in patients with history of poor fertilization.

Authors:  Rony T Elias; Nigel Pereira; Lisa Artusa; Amelia G Kelly; Monica Pasternak; Jovana P Lekovich; Gianpiero D Palermo; Zev Rosenwaks
Journal:  J Assist Reprod Genet       Date:  2017-04-13       Impact factor: 3.412

4.  Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2015-08-21       Impact factor: 4.234

5.  Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

Authors:  Bülent Gülekli; Funda Göde; Zerrin Sertkaya; Ahmet Zeki Işık
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

6.  Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Anuja Dokras
Journal:  Fertil Steril       Date:  2014-11-06       Impact factor: 7.329

Review 7.  Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger).

Authors:  Sofia Andrade de Oliveira; Vinícius Fernando Calsavara; Gemma Castillón Cortés
Journal:  JBRA Assist Reprod       Date:  2016-12-01

8.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

9.  Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.

Authors:  Yu-Hung Lin; Mei-Zen Huang; Jiann-Loung Hwang; Heng-Ju Chen; Bih-Chwen Hsieh; Lee-Wen Huang; Chii-Ruey Tzeng; Kok-Min Seow
Journal:  J Assist Reprod Genet       Date:  2013-04-20       Impact factor: 3.412

10.  An update on the prevention of ovarian hyperstimulation syndrome.

Authors:  Omar El Tokhy; Julia Kopeika; Tarek El-Toukhy
Journal:  Womens Health (Lond)       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.